Kate Sumpter

3.3k total citations · 1 hit paper
24 papers, 1.2k citations indexed

About

Kate Sumpter is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kate Sumpter has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Kate Sumpter's work include Gastric Cancer Management and Outcomes (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Esophageal Cancer Research and Treatment (7 papers). Kate Sumpter is often cited by papers focused on Gastric Cancer Management and Outcomes (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Esophageal Cancer Research and Treatment (7 papers). Kate Sumpter collaborates with scholars based in United Kingdom, Netherlands and Italy. Kate Sumpter's co-authors include David Cunningham, S M Griffin, Debasish Das, Mark Hudson, Stephen Stewart, Jessica Dyson, Tariq Aslam, John Rose, Rajiv Lochan and Helen L. Reeves and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Journal of Hepatology.

In The Last Decade

Kate Sumpter

24 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team

2013 412 citations Jessica Dyson, Rajiv Lochan et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kate Sumpter United Kingdom	13	483	431	427	381	332	24	1.2k
Kazuho Imanaka Japan	14	306 0.6×	344 0.8×	242 0.6×	171 0.4×	354 1.1×	29	901
Jeremy French United Kingdom	20	337 0.7×	480 1.1×	584 1.4×	521 1.4×	322 1.0×	63	1.4k
Guellue Cataldegirmen Germany	14	386 0.8×	214 0.5×	685 1.6×	750 2.0×	95 0.3×	17	1.2k
Linda Stadheim United States	14	537 1.1×	589 1.4×	758 1.8×	329 0.9×	609 1.8×	21	1.5k
Stephen J. Rulyak United States	16	195 0.4×	230 0.5×	411 1.0×	495 1.3×	50 0.2×	25	993
Annette Jappe Switzerland	11	242 0.5×	193 0.4×	280 0.7×	227 0.6×	354 1.1×	14	1.1k
Tadahisa Inoue Japan	18	491 1.0×	198 0.5×	557 1.3×	250 0.7×	68 0.2×	123	889
Woohyung Lee South Korea	23	725 1.5×	156 0.4×	953 2.2×	764 2.0×	418 1.3×	126	1.5k
Francis Navarro France	17	192 0.4×	165 0.4×	388 0.9×	213 0.6×	246 0.7×	43	773
Gen Tanabe Japan	19	183 0.4×	392 0.9×	429 1.0×	221 0.6×	511 1.5×	59	1.0k

Countries citing papers authored by Kate Sumpter

Since Specialization

Citations

This map shows the geographic impact of Kate Sumpter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Sumpter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Sumpter more than expected).

Fields of papers citing papers by Kate Sumpter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate Sumpter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Sumpter. The network helps show where Kate Sumpter may publish in the future.

Co-authorship network of co-authors of Kate Sumpter

This figure shows the co-authorship network connecting the top 25 collaborators of Kate Sumpter. A scholar is included among the top collaborators of Kate Sumpter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Sumpter. Kate Sumpter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Navidi, Maziar, Alexander W. Phillips, S M Griffin, et al.. (2018). Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer. British journal of surgery. 105(7). 900–906. 44 indexed citations

Cunningham, David, Sally Stenning, Elizabeth Smyth, et al.. (2017). Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. The Lancet Oncology. 18(3). 357–370. 197 indexed citations

Qian, W., Juan W. Valle, Denis Talbot, et al.. (2016). Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial. Annals of Oncology. 27. vi146–vi146. 2 indexed citations

Smyth, Elizabeth, Samuel Rowley, William Allum, et al.. (2016). A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948). Annals of Oncology. 27. vi562–vi562. 2 indexed citations

King, James P., Daniel H. Palmer, Philip J. Johnson, et al.. (2016). Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit. Clinical Oncology. 29(4). 256–262. 28 indexed citations

Edeline, Julien, Jean‐Frédéric Blanc, Philip J. Johnson, et al.. (2016). A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver International. 36(12). 1821–1828. 75 indexed citations

Lagarde, Sjoerd M., Maziar Navidi, Suzanne S. Gisbertz, et al.. (2016). Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy. British journal of surgery. 103(12). 1658–1664. 15 indexed citations

Cunningham, David, Sally Stenning, Leanne Stevenson, et al.. (2015). 2201 Peri-operative chemotherapy ± bevacizumab for resectable gastro-oesophageal adenocarcinoma: Results from the UK Medical Research Council randomised ST03 trial (ISRCTN 46020948). European Journal of Cancer. 51. S400–S400. 23 indexed citations

Dyson, Jessica, Rajiv Lochan, Janine Graham, et al.. (2013). Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. Journal of Hepatology. 60(1). 110–117. 412 indexed citations breakdown →

10.

Rao, Sheela, Naureen Starling, David Cunningham, et al.. (2010). Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Annals of Oncology. 21(11). 2213–2219. 86 indexed citations

11.

Evans, T.R. Jeffry, et al.. (2006). A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen. Journal of Clinical Oncology. 24(18_suppl). 4081–4081. 6 indexed citations

12.

Sumpter, Kate, Catherine Harper‐Wynne, David Cunningham, et al.. (2005). Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. British Journal of Cancer. 92(11). 1976–1983. 109 indexed citations

13.

Price, Timothy, Paul J. Ross, Tamas Hickish, et al.. (2004). Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal Carcinoma. Clinical Colorectal Cancer. 3(4). 235–242. 29 indexed citations

14.

Parton, Marina, N. Maisey, Susana Banerjee, et al.. (2004). Gefitinib in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience. Journal of Clinical Oncology. 22(14_suppl). 7099–7099. 2 indexed citations

15.

Chau, Ian, Mark Allen, David Cunningham, et al.. (2003). Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. British Journal of Cancer. 88(7). 1017–1024. 65 indexed citations

16.

Harper‐Wynne, Catherine, Kate Sumpter, Mary O’Brien, et al.. (2003). P-356 Addition of SRL172 (Mycobacterium vaccae) to standard chemotherapy in small cell lung cancer (SCLC) confers no survival benefit: Results of a randomised multicentre study. Lung Cancer. 41. S181–S182. 2 indexed citations

17.

Sumpter, Kate, Catherine Harper‐Wynne, David Cunningham, et al.. (2003). randomised, multicenter phase-iii study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation : 1031. 26. 18 indexed citations

18.

Price, Timothy, Mark Hill, A. Norman, Kate Sumpter, & David Cunningham. (2002). The Royal Marsden Experience of the Use of Carboplatin in Oesophageal Carcinoma. 4(1). 23–26. 1 indexed citations

19.

Sumpter, Kate & David Cunningham. (2000). Combination chemotherapy and colorectal cancer.. PubMed. 27(5 Suppl 10). 105–11. 3 indexed citations

20.

Sumpter, Kate, R Powles, Noopur Raje, et al.. (1999). Oral Idarubicin as a Single Agent Therapy in Patients with Relapsed or Resistant Multiple Myeloma. Leukemia & lymphoma. 35(5-6). 593–597. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact